Worse QoL seen in hidradenitis suppurativa than psoriasis patients
It appears that patients with psoriasis have lesser health-related quality of life (HRQoL) burden than those with hidradenitis suppurativa (HS), a recent study has found.
“This study clearly documents the needs of patients with HS and the potential impact of medical, scientific and societal consensus for the development of more effective HS treatments,” the investigators said.
To determine which diseases were associated with more severe HRQoL impairment, the investigators determined and compared weighted averages of each of the following baseline HRQoL measures between HS and psoriasis populations from five clinical trials: Visual Analogue Scale (VAS) for pain, Total Work Productivity Impairment, Dermatology Life Quality Index, EuroQOL 5D VAS and Short Form-36 Health Survey.
Patients with HS had higher scores for VAS-pain (54.3 vs 36.1 percent; p<0.001), Dermatology Life Quality Index (15.3 vs 11.3; p<0.0001), EuroQOL 5D VAS (58.8 vs 50.8; p<0.0002) and Total Work Productivity Impairment (35.4 vs 18.2) than did those with psoriasis. On the other hand, patients with psoriasis had higher Short Form-36 Health Survey scores compared with those with HS (physical, 39.6 vs 49.0; mental, 41.5 vs 47.5; p<0.0001 for both).
These findings should be taken in light of some limitations, such as the use of published summary data instead of patient-level data for the analysis, as well as the comparison of weighted pooled averages.
“Psoriasis and HS exhibit distinct clinical features, but no studies have directly compared the HRQoL in patients with moderate-to-severe manifestations of these conditions,” the investigators said.